Similar articles for PMID: 30552200

Year	Number of Results
2007	1
2009	1
2010	2
2011	5
2012	3
2013	6
2014	6
2015	4
2016	17
2017	32
2018	28
2019	36
2020	41
2021	62
2022	50
2023	21
2024	0

1

Rapid Modulation of PSMA Expression by Androgen Deprivation: Serial ⁶⁸Ga-PSMA-11 PET in Men with Hormone-Sensitive and Castrate-Resistant Prostate Cancer Commencing Androgen Blockade.

Emmett L, Yin C, Crumbaker M, Hruby G, Kneebone A, Epstein R, Nguyen Q, Hickey A, Ihsheish N, O'Neill G, Horvath L, Chalasani V, Stricker P, Joshua AM. Emmett L, et al. J Nucl Med. 2019 Jul;60(7):950-954. doi: 10.2967/jnumed.118.223099. Epub 2018 Dec 14. J Nucl Med. 2019. PMID: 30552200 Free article. Clinical Trial.

2

Heterogeneous Flare in Prostate-specific Membrane Antigen Positron Emission Tomography Tracer Uptake with Initiation of Androgen Pathway Blockade in Metastatic Prostate Cancer.

Aggarwal R, Wei X, Kim W, Small EJ, Ryan CJ, Carroll P, Cooperberg M, Evans MJ, Hope T. Aggarwal R, et al. Eur Urol Oncol. 2018 May;1(1):78-82. doi: 10.1016/j.euo.2018.03.010. Epub 2018 May 15. Eur Urol Oncol. 2018. PMID: 31100231

3

More advantages in detecting bone and soft tissue metastases from prostate cancer using ¹⁸F-PSMA PET/CT.

Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE. Pianou NK, et al. Hell J Nucl Med. 2019 Jan-Apr;22(1):6-9. doi: 10.1967/s002449910952. Epub 2019 Mar 7. Hell J Nucl Med. 2019. PMID: 30843003 Free article.

4

Evaluation of PSMA expression changes on PET/CT before and after initiation of novel antiandrogen drugs (enzalutamide or abiraterone) in metastatic castration-resistant prostate cancer patients.

Plouznikoff N, Artigas C, Sideris S, Martinez Chanza N, Gil T, Peltier A, Flamen P. Plouznikoff N, et al. Ann Nucl Med. 2019 Dec;33(12):945-954. doi: 10.1007/s12149-019-01404-2. Epub 2019 Oct 5. Ann Nucl Med. 2019. PMID: 31587172

5

Antihormone treatment differentially regulates PSA secretion, PSMA expression and ⁶⁸Ga-PSMA uptake in LNCaP cells.

Mathy CS, Mayr T, Kürpig S, Meisenheimer M, Dolscheid-Pommerich RC, Stoffel-Wagner B, Kristiansen G, Essler M, Muders MH, Bundschuh RA. Mathy CS, et al. J Cancer Res Clin Oncol. 2021 Jun;147(6):1733-1743. doi: 10.1007/s00432-021-03583-w. Epub 2021 Mar 24. J Cancer Res Clin Oncol. 2021. PMID: 33760944 Free PMC article.

6

ENZA-p trial protocol: a randomized phase II trial using prostate-specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901).

Emmett L, Subramaniam S, Joshua AM, Crumbaker M, Martin A, Zhang AY, Rana N, Langford A, Mitchell J, Yip S, Francis R, Hofman MS, Sandhu S, Azad A, Gedye C, McJannett M, Stockler MR, Davis ID; Australian, New Zealand Urogenital, Prostate Cancer Trials Group (ANZUP), the ENZA-p investigators. Emmett L, et al. BJU Int. 2021 Nov;128(5):642-651. doi: 10.1111/bju.15491. Epub 2021 Jul 6. BJU Int. 2021. PMID: 34028967

7

Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography in Men with Nonmetastatic Castration-Resistant Prostate Cancer.

Fendler WP, Weber M, Iravani A, Hofman MS, Calais J, Czernin J, Ilhan H, Saad F, Small EJ, Smith MR, Perez PM, Hope TA, Rauscher I, Londhe A, Lopez-Gitlitz A, Cheng S, Maurer T, Herrmann K, Eiber M, Hadaschik B. Fendler WP, et al. Clin Cancer Res. 2019 Dec 15;25(24):7448-7454. doi: 10.1158/1078-0432.CCR-19-1050. Epub 2019 Sep 11. Clin Cancer Res. 2019. PMID: 31511295

8

Immunohistochemical Validation of PSMA Expression Measured by ⁶⁸Ga-PSMA PET/CT in Primary Prostate Cancer.

Woythal N, Arsenic R, Kempkensteffen C, Miller K, Janssen JC, Huang K, Makowski MR, Brenner W, Prasad V. Woythal N, et al. J Nucl Med. 2018 Feb;59(2):238-243. doi: 10.2967/jnumed.117.195172. Epub 2017 Aug 3. J Nucl Med. 2018. PMID: 28775203 Free article.

9

The role of (⁶⁸Ga)PSMA I&T in biochemical recurrence after radical prostatectomy: detection rate and the correlation between the level of PSA, Gleason score, and the SUV_max.

Yilmaz U, Komek H, Can C, Altindag S. Yilmaz U, et al. Ann Nucl Med. 2019 Aug;33(8):545-553. doi: 10.1007/s12149-019-01360-x. Epub 2019 May 8. Ann Nucl Med. 2019. PMID: 31069696

10

Enzalutamide Enhances PSMA Expression of PSMA-Low Prostate Cancer.

Staniszewska M, Fragoso Costa P, Eiber M, Klose JM, Wosniack J, Reis H, Szarvas T, Hadaschik B, Lückerath K, Herrmann K, Fendler WP, Iking J. Staniszewska M, et al. Int J Mol Sci. 2021 Jul 11;22(14):7431. doi: 10.3390/ijms22147431. Int J Mol Sci. 2021. PMID: 34299051 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

266 results

Results by year